Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Salmon Calcitonin Use and Associated Cancer Risk

Overman, Robert A., Borse, Mrudula, Gourlay, Margaret L. · 2013 · Annals of Pharmacotherapy

Abstract

Objective: To evaluate the strength of evidence supporting a possible association between salmon calcitonin (SCT) use and cancer incidence. Data Sources: Searches of MEDLINE/PubMed, MEDLINE/OVID, and EMBASE (January 1973 to September 2013) were performed using the key search terms salmon calcitonin, humans, nasal calcitonin, and (for EMBASE only) randomized controlled trial. We also performed a manual review of data reviewed by the US Food and Drug Administration (FDA) committee in 2013. Study Selection and Data Extraction: All articles identified from the data sources were evaluated and all information deemed relevant was included for this review. Data Synthesis: Intranasal and injectable SCT are FDA-approved for the treatment of postmenopausal osteoporosis. After a safety signal suggested a possible link between SCT use and prostate cancer, the European Medicines Agency and FDA regulatory agencies conducted analyses of SCT randomized controlled trial data to assess cancer-related adverse events and to readdress the approval status of SCT. Eighteen studies were found that compared nasal or oral SCT and placebo. In 15 of the 18 studies, the percentage of malignancy was greater in the SCT arm. The studies varied in quality, outcomes, and length. Most of the studies had poor-quality methods to assess new cancer cases. Conclusions: Current evidence may suggest an association between SCT use and cancer incidence based on studies with poor-quality cancer assessment methods. However, considering the lack of demonstrated efficacy of SCT to reduce fractures, clinicians should consider discontinuing its use for osteoporosis treatment regardless of the FDA’s final approval decision.

Overview

Integrity signals

Registry

Crossref · 10.1177/1060028013509233

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 7

  1. Copp DH, 1994, Clin Invest Med, 17, 268
  2. Watts NB, 2004, J Manag Care Pharm, 10, 142
  3. 10.1002/(SICI)1097-0045(19970215)30:3<183::AID-PROS6>3.0.CO;2-N · doi:10.1002/(sici)1097-0045(19970215)30:3<183::aid-pros6>3.0.co;2-n
  4. Segawa N, 2001, Cancer Res, 61, 6060
  5. 10.1002/jbmr.1852 · DOI
  6. Wells GA, 2008, Cochrane Database Syst Rev, CD001155
  7. Wells G, 2008, Cochrane Database Syst Rev, CD004523

Cited by

See all 96

Metadata

Authors
Overman, R. A., Borse, M., & Gourlay, M. L.
Affiliations
University of North Carolina at Chapel Hill (US)
Venue
Annals of Pharmacotherapy
Published
2013-10-25
Volume
47
Issue
12
Pages
1675-1684
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2105919535
Cited by
96
References
42
Citations by year
2026: 4 · 2025: 5 · 2024: 6 · 2023: 1 · 2022: 8 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 12 · 2016: 14 · 2015: 13 · 2014: 8 · 2013: 1
FWCI
1.98
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Annals of Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
salmon calcitonin, cancer risk, postmenopausal osteoporosis, intranasal calcitonin, prostate cancer, drug safety, randomized controlled trials, cancer incidence, FDA drug approval, fracture prevention
MeSH terms
Calcitonin, Humans, Neoplasms, Osteoporosis, Risk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Salmon Calcitonin Use and Associated Cancer Risk. https://app.cochat.ai/papers/10.1177/1060028013509233
The paper
Overman, R. A., Borse, M., & Gourlay, M. L. (2013). Salmon Calcitonin Use and Associated Cancer Risk. Annals of Pharmacotherapy. https://doi.org/10.1177/1060028013509233

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.